311 related articles for article (PubMed ID: 17314171)
21. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
22. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".
Rösler C; Köck J; Malim MH; Blum HE; von Weizsäcker F
Science; 2004 Sep; 305(5689):1403; author reply 1403. PubMed ID: 15353783
[No Abstract] [Full Text] [Related]
23. APOBEC3 inhibits mouse mammary tumour virus replication in vivo.
Okeoma CM; Lovsin N; Peterlin BM; Ross SR
Nature; 2007 Feb; 445(7130):927-30. PubMed ID: 17259974
[TBL] [Abstract][Full Text] [Related]
24. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
[TBL] [Abstract][Full Text] [Related]
25. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
Soros VB; Yonemoto W; Greene WC
PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
[TBL] [Abstract][Full Text] [Related]
26. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.
Henry M; Guétard D; Suspène R; Rusniok C; Wain-Hobson S; Vartanian JP
PLoS One; 2009; 4(1):e4277. PubMed ID: 19169351
[TBL] [Abstract][Full Text] [Related]
27. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha.
Sarkis PT; Ying S; Xu R; Yu XF
J Immunol; 2006 Oct; 177(7):4530-40. PubMed ID: 16982890
[TBL] [Abstract][Full Text] [Related]
28. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
29. The potential role of APOBEC3G in limiting replication of hepatitis B virus.
Mohamadkhani A; Pourdadash A; Tayebi S; Estakhri A; Nazem H; Sotoudeh M; Poustchi H
Arab J Gastroenterol; 2012 Dec; 13(4):170-3. PubMed ID: 23432984
[TBL] [Abstract][Full Text] [Related]
30. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.
Kitamura K; Wang Z; Chowdhury S; Simadu M; Koura M; Muramatsu M
PLoS Pathog; 2013; 9(5):e1003361. PubMed ID: 23696735
[TBL] [Abstract][Full Text] [Related]
31. A3G-induced mutations show a low prevalence and exhibit plus-strand regional distribution in hepatitis B virus DNA from patients with non-hepatocellular carcinoma (HCC) and HCC.
Ren F; Li W; Zhao S; Wang L; Wang Q; Li M; Xiang A; Guo Y
J Med Virol; 2021 Jun; 93(6):3672-3678. PubMed ID: 32779759
[TBL] [Abstract][Full Text] [Related]
32. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
33. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
Bonvin M; Achermann F; Greeve I; Stroka D; Keogh A; Inderbitzin D; Candinas D; Sommer P; Wain-Hobson S; Vartanian JP; Greeve J
Hepatology; 2006 Jun; 43(6):1364-74. PubMed ID: 16729314
[TBL] [Abstract][Full Text] [Related]
34. The inhibition of hepatitis B virus by APOBEC cytidine deaminases.
Janahi EM; McGarvey MJ
J Viral Hepat; 2013 Dec; 20(12):821-8. PubMed ID: 24304451
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Bonvin M; Greeve J
Curr Opin Infect Dis; 2008 Jun; 21(3):298-303. PubMed ID: 18448976
[TBL] [Abstract][Full Text] [Related]
36. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
Yu Q; König R; Pillai S; Chiles K; Kearney M; Palmer S; Richman D; Coffin JM; Landau NR
Nat Struct Mol Biol; 2004 May; 11(5):435-42. PubMed ID: 15098018
[TBL] [Abstract][Full Text] [Related]
37. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules.
Gallois-Montbrun S; Kramer B; Swanson CM; Byers H; Lynham S; Ward M; Malim MH
J Virol; 2007 Mar; 81(5):2165-78. PubMed ID: 17166910
[TBL] [Abstract][Full Text] [Related]
38. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
39. Human-APOBEC3G-dependent restriction of porcine endogenous retrovirus replication is mediated by cytidine deamination and inhibition of DNA strand transfer during reverse transcription.
Jin SY; Choi HY; Kim HS; Jung YT
Arch Virol; 2018 Jul; 163(7):1907-1914. PubMed ID: 29610985
[TBL] [Abstract][Full Text] [Related]
40. [The innate antiretroviral defense of human cells, based on the DNA editing].
Pupecka M; Pacak A
Postepy Biochem; 2006; 52(3):247-52. PubMed ID: 17201059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
